McLaughlin-Taylor E, Pande H, Forman S J, Tanamachi B, Li C R, Zaia J A, Greenberg P D, Riddell S R
Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA 91010.
J Med Virol. 1994 May;43(1):103-10. doi: 10.1002/jmv.1890430119.
Primary cytomegalovirus (CMV) infection and reactivation of persistent CMV are associated with significant morbidity and mortality in immunocompromised individuals. Although recovery from CMV disease is correlated with the development of CMV-specific cytotoxic T lymphocytes (CTL), the major viral target antigens to which the response is directed are ill-defined, though they may comprise viral structural elements. We now identify the CMV matrix protein pp65 as a significant target antigen for CD8+ class I major histocompatibility complex (MHC)-restricted CMV-specific CTL derived from the peripheral blood of four of five latently infected individuals. CMV-specific CTL recognition of pp65 on target cells occurs prior to the onset of viral gene expression and persists throughout the duration of the replicative cycle. Recognition in the absence of viral gene expression suggests that abundant viral protein enters the normal trafficking pathway upon viral penetration and is readily made available to MHC molecules for presentation at the cell surface. Thus pp65 specific CTL may represent an important effector population for early control and limitation of CMV infection and disease. The observation that CMV-specific CTL can be induced in vitro using peptide fragments derived from pp65 supports the future use and manipulation of this and similar effector populations in a clinical setting.
原发性巨细胞病毒(CMV)感染以及持续性CMV的再激活与免疫功能低下个体的显著发病率和死亡率相关。虽然从CMV疾病中恢复与CMV特异性细胞毒性T淋巴细胞(CTL)的发育相关,但CTL应答所针对的主要病毒靶抗原尚不明确,尽管它们可能包含病毒结构成分。我们现在确定CMV基质蛋白pp65是来自五名潜伏感染个体中四名个体外周血的CD8⁺ Ⅰ类主要组织相容性复合体(MHC)限制性CMV特异性CTL的重要靶抗原。靶细胞上pp65的CMV特异性CTL识别发生在病毒基因表达开始之前,并在整个复制周期持续存在。在没有病毒基因表达的情况下的识别表明,大量病毒蛋白在病毒穿透后进入正常运输途径,并很容易被MHC分子用于在细胞表面呈递。因此,pp65特异性CTL可能代表早期控制和限制CMV感染及疾病的重要效应细胞群体。使用源自pp65的肽片段可在体外诱导CMV特异性CTL这一观察结果支持了在临床环境中对该效应细胞群体及类似效应细胞群体的未来应用和操控。